⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
COGT News
Cogent Biosciences, Inc. Common Stock
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
globenewswire.com
COGT
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
globenewswire.com
COGT
Cogent Launches Zero Day Response and Autonomous Remediation, Closing the Gap Between Vulnerability Disclosure and Confirmed Fix
prnewswire.com
COGT
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
globenewswire.com
COGT
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
globenewswire.com
COGT
Form 8-K
sec.gov
COGT
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
globenewswire.com
COGT
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
globenewswire.com
COGT
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
globenewswire.com
COGT
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
globenewswire.com
COGT